BioPharma Resources

Drugs by condition

Drugs approved for obesity and weight management

Brand-name prescription drugs and biologics whose FDA label lists obesity and weight management as an approved use. Matched on the label phrases: "chronic weight management", "obesity".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

15

Still marketed, NDA or BLA

Drug classes

5

Novel drugs

7

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for obesity and weight management.

  • Foundayo (Orforglipron Calcium) · Eli Lilly and CO NovelApr 1, 2026
  • Arynta (Lisdexamfetamine Dimesylate) · Azurity Jun 16, 2025
  • Zepbound (Tirzepatide) · Eli Lilly and CO NovelBreakthrough therapyPriority reviewNov 8, 2023
  • Wegovy (Semaglutide) · Novo NovelBreakthrough therapyAccelerated approvalPriority reviewJun 4, 2021
  • Imcivree (Setmelanotide Acetate) · Rhythm NovelBreakthrough therapyPriority reviewOrphanNov 25, 2020

All approved drugs for obesity and weight management, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 68 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (1)

  • Zepbound Tirzepatide · Eli Lilly and CO · 2023

Melanocortin 4 Receptor Agonist (1)

  • Imcivree Setmelanotide Acetate · Rhythm · 2020

GLP-1 Receptor Agonist (1)

  • Saxenda Liraglutide · Novo · 2014

Intestinal Lipase Inhibitor (1)

  • Xenical Orlistat · Cheplapharm · 1999

Class not listed in FDA's data (11)

  • Foundayo Orforglipron Calcium · Eli Lilly and CO · 2026
  • Wegovy Semaglutide · Novo · 2021
  • Vyvanse Lisdexamfetamine Dimesylate · Takeda Pharms USA · 2007
  • Arynta Lisdexamfetamine Dimesylate · Azurity · 2025
  • Vyvanse Lisdexamfetamine Dimesylate · Takeda Pharms USA · 2017
  • Contrave Bupropion Hydrochloride, Naltrexone Hydrochloride · Azurity · 2014
  • Qsymia Phentermine Hydrochloride, Topiramate · Vivus LLC · 2012
  • Phendimetrazine Tartrate Phendimetrazine Tartrate · Acertis Pharms · 1979
  • Pregnyl Gonadotropin, Chorionic · Organon USA LLC · 1976
  • Chorionic Gonadotropin Gonadotropin, Chorionic · Ferring · 1974
  • Chorionic Gonadotropin Gonadotropin, Chorionic · Fresenius Kabi USA · 1973

Drugs in development for obesity and weight management

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • BerobenatidePF-08653944, MET097Phase 319 trials

    Pfizer · Obesity, Overweight and/or Obesity, Overweight

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • Maridebart cafraglutideAMG 133Phase 314 trials

    Amgen · Obesity, Overweight, Obstructive Sleep Apnea

  • EloralintideLY3841136Phase 313 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • NNC0487-0111Phase 312 trials

    Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea

  • BofanglutideGZR18, BofanglutidaPhase 311 trials

    Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • ElecoglipronPhase 39 trials

    AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight

  • LenbelintideAZD6234Phase 39 trials

    AstraZeneca · Obesity or Overweight, Obesity, Overweight

  • Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea

  • ZenagamtidePhase 39 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • EcnoglutideXW003, VRB-101Phase 38 trials

    Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea

  • IBI362Phase 38 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea

  • OlatorepatideHS-20094Phase 38 trials

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes

  • AleniglipronPhase 36 trials

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management

  • CagriSemaCagrilintide B and Semaglutide IPhase 36 trials

    Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension

  • LUM-201Phase 36 trials

    Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight

More on obesity and weight management: recruiting trials · published research

Related in cardiovascular and metabolic: Type 2 diabetes · Type 1 diabetes · High blood pressure (hypertension) · Heart failure · High cholesterol · High triglycerides · Atrial fibrillation · Blood clots (DVT and pulmonary embolism) · Stroke prevention · Coronary artery disease and heart attack

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.